Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CWBR CohBar	$0.41	$0.41	$0.00 ▼ $1.01	$1.19M	1.39	4,364 shs	N/A
PALI Palisade Bio	$0.75 +3.9%	$0.82	$0.60 ▼ $4.32	$6.88M	1.35	5.51 million shs	207,588 shs
TTNP Titan Pharmaceuticals	$4.83 -1.4%	$4.44	$3.03 ▼ $8.44	$6.64M	1.29	51,600 shs	1,952 shs
VIVS VivoSim Labs	$2.11 +6.6%	$1.78	$1.41 ▼ $21.96	$5.49M	0.94	45,311 shs	46,081 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CWBR CohBar	0.00%	0.00%	0.00%	0.00%	-3.53%
PALI Palisade Bio	0.00%	-5.87%	-32.07%	-6.57%	-78.94%
TTNP Titan Pharmaceuticals	0.00%	-3.23%	-5.87%	+9.13%	-40.38%
VIVS VivoSim Labs	0.00%	+19.21%	-4.52%	+210,999,900.00%	+210,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CWBR CohBar	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	2.4556 of 5 stars	3.5	4.0	0.0	0.0	2.0	0.0	0.6
TTNP Titan Pharmaceuticals	0.3463 of 5 stars	0.0	3.0	0.0	0.0	2.8	0.0	0.0
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CWBR CohBar	0.00	N/A	N/A	N/A
PALI Palisade Bio	3.00	Buy	$12.00	1,491.51% Upside
TTNP Titan Pharmaceuticals	0.00	N/A	N/A	N/A
VIVS VivoSim Labs	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CWBR CohBar	N/A	N/A	N/A	N/A	$5.27 per share	N/A
PALI Palisade Bio	$250K	27.51	N/A	N/A	$0.29 per share	2.60
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	$2.10 per share	N/A
VIVS VivoSim Labs	$140K	39.19	N/A	N/A	$3.67 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CWBR CohBar	-$12.18M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	-$14.44M	-$4.06	N/A	N/A	N/A	N/A	-214.94%	-135.09%	11/11/2025 (Estimated)
TTNP Titan Pharmaceuticals	-$4.71M	-$2.95	N/A	∞	N/A	N/A	-108.60%	-95.64%	N/A
VIVS VivoSim Labs	-$2.48M	-$10.20	N/A	∞	N/A	-1,396.48%	-32.95%	-21.31%	N/A

Latest CWBR, PALI, TTNP, and VIVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TTNP Titan Pharmaceuticals	N/A	-$0.65	N/A	-$0.65	N/A	N/A
8/12/2025	Q1 2026	VIVS VivoSim Labs	N/A	-$1.14	N/A	-$1.14	N/A	$0.04 million
8/11/2025	Q2 2025	PALI Palisade Bio	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CWBR CohBar	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CWBR CohBar	N/A	N/A	N/A
PALI Palisade Bio	N/A	1.62	1.62
TTNP Titan Pharmaceuticals	N/A	11.60	7.73
VIVS VivoSim Labs	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CWBR CohBar	2.47%
PALI Palisade Bio	11.79%
TTNP Titan Pharmaceuticals	31.49%
VIVS VivoSim Labs	8.23%

Insider Ownership

Company	Insider Ownership
CWBR CohBar	6.51%
PALI Palisade Bio	3.28%
TTNP Titan Pharmaceuticals	0.72%
VIVS VivoSim Labs	3.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CWBR CohBar	10	2.91 million	N/A	Not Optionable
PALI Palisade Bio	10	9.12 million	8.82 million	Not Optionable
TTNP Titan Pharmaceuticals	10	1.33 million	1.32 million	Optionable
VIVS VivoSim Labs	20	2.60 million	2.50 million	N/A

CWBR, PALI, TTNP, and VIVS Headlines

Recent News About These Companies

VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | finanznachrichten.de

VivoSim appoints Lialin as Chief Commercial Officer

August 14, 2025 | msn.com

VivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing Services

August 14, 2025 | quiverquant.comQ

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | financialpost.comF

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | globenewswire.com

VivoSim: Fiscal Q1 Earnings Snapshot

August 12, 2025 | timesunion.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

CWBR, PALI, TTNP, and VIVS Company Descriptions

CohBar NASDAQ:CWBR

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

Palisade Bio NASDAQ:PALI

$0.75 +0.03 (+3.86%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.75 -0.01 (-0.66%)

As of 08/22/2025 07:59 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Titan Pharmaceuticals NASDAQ:TTNP

$4.83 -0.07 (-1.45%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$4.83 +0.00 (+0.02%)

As of 08/22/2025 06:31 PM Eastern

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

VivoSim Labs NASDAQ:VIVS

$2.11 +0.13 (+6.57%)

As of 08/22/2025 03:59 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time